Pancreatic cancer is characterized by a desmoplastic reaction that creates a dense fibroinflammatory microenvironment, promoting hypoxia and limiting cancer drug delivery due to decreased blood perfusion. Here we describe a novel tumor-stroma interaction that may help explain the prevalence of desmoplasia in this cancer. Specifically, we found that activation of HIF-1α by tumor hypoxia strongly activates secretion of the sonic hedgehog ligand SHH by cancer cells which in turn causes stromal fibroblasts to increase fibrous tissue deposition. In support of this finding, elevated levels of HIF-1α and SHH in pancreatic tumors were determined to be markers of decreased patient survival. Repeated cycles of hypoxia and desmoplasia amplified each other in a feed forward loop that made tumors more aggressive and resistant to therapy. This loop could be blocked by HIF-1α inhibition, which was sufficient to block SHH production and HH signaling. Taken together, our findings suggest that increased HIF-1α produced by hypoxic tumors triggers the desmoplasic reaction in pancreatic cancer, which is then amplified by a feed forward loop involving cycles of decreased blood flow and increased hypoxia. our findings strengthen the rationale for testing HIF inhibitors may therefore represent a novel therapeutic option for pancreatic cancer.
INTRODUCTION
Pancreatic cancer is a devastating disease with the majority of patients succumbing within one year of diagnosis (1) . Surgical resection offers the only curative therapy but is an option for less than 20 % of patients and yields actuarial 5-year survival rates of only about 20%
(2). Treatment failure due to local recurrence and hepatic metastases can occur within 1 to 2 years after surgery (3) . Other treatment options including gemcitabine and erlotinib offer only a small survival advantage (4) and the overall 5 year survival rate for patients with pancreatic cancer across all stages remains 0.4 to 4 %, making pancreatic cancer one of the top causes of death from cancer in the Western world (5) .
A characteristic of pancreatic cancer is extensive desmoplasia comprising a dense stromal fibroinflammatory reaction of fibroblasts, inflammatory cells and tumor vasculature (6) .
Desmoplasia leads to decreased blood supply, poor drug delivery (7) and hypoxia (8) . Although hypoxia presents a particularly hostile environment for cell growth, cancer cells are able to adapt and survive by increasing the expression of genes responsible for anaerobic metabolism, cell survival, metastasis, and formation of new blood vessels (9). The cellular response to hypoxia is mediated through a rapid increase in the levels of the transcription factors hypoxia inducible factor-1 (HIF-1) and HIF-2. HIFs are heterodimers of inducible α and constitutive β subunits. The importance of HIF-1α to pancreatic cancer is directly demonstrated by the resistance to chemotherapy and radiation seen in pancreatic cancer cells constitutively expressing HIF-1α, and their increased in vivo tumorigenicity (8) .
(HH) signaling plays an important role in the communication between tumor and stroma cells and promotes tumorigenesis (10-13). HH signaling is initiated by binding of SHH ligand to the
Patched-1 receptor (PTCH1) that relieves repression of the transducer protein Smoothened (SMO), thus triggering activation of the GLI family of transcription factors. Genes activated by GLI include GLI-1 itself, PTCH1 and depending on the cell type, genes upregulating cell proliferation, survival, angiogenesis and through SNAIL the epithelial-mesenchyme transition of metastasis (14) .
Altered HH signaling has been implicated in the development of approximately 20-25% of all cancers and has been classified into two major types (15, 16) . The first type includes mutations in HH network genes resulting in HH ligand-independent tumors, they include PTCH inactivating mutations, SMO activating mutations, or loss of REN KCTD11 , a GLI antagonist, in medulloblastoma (16, 17) . The second type is HH ligand-dependent tumors characterized by aberrant expression of HH ligand that is observed especially in cancers of the gastrointestinal tract (including pancreas), breast, colon and prostate (16, 18) . In some cases the tumors have been proposed to respond to HH ligand in an autocrine manner as HH ligand has been found to be both produced by the tumor cells and to activate them (16) . In contrast, others have described paracrine models where the HH ligand is produced by the tumor cells (HH-producing cell) but acts on the fibroblasts and stellate cells in the stroma (HH-responding cells) (10-13, 19).
SHH and downstream components of the HH signaling pathway have been shown to be present in precursor lesions and primary pancreatic tumors but not in normal pancreas, suggesting that hedgehog signaling may play a role in the initiation and progression of pancreatic cancer (20) (21) (22) . This concept is supported by the finding that mouse transgenic models with SHH expressed in pancreatic epithelium, together with mutant KRAS, show an Author Manuscript Published OnlineFirst on April 30, 2013; DOI: 10.1158/0008-5472. CAN-11-1433 enhanced incidence of pancreatic intraepithelial neoplasia and increased lethality (23) .
Furthermore, expression of SHH in transformed primary pancreatic ductal epithelial cells in an orthotopic model of pancreatic cancer leads to increased desmoplasia (11). Inhibition of HH signaling was shown to enhance vascular density and delivery of chemotherapy in a mouse model of pancreatic cancer (24) and to inhibit tumor initiation and metastasis in orthotopic xenografts established from human pancreatic cancer cell lines (25) .
While it has become clear that aberrant activation of HH signaling either by mutations or ligand overexpression can lead to cancer, the mechanisms responsible for regulating SHH expression in human cancer are poorly understood (26) (27) (28) . We show here that hypoxia, acting through HIF-1α is responsible for the increase in SHH in pancreatic cancer cells. Moreover, we show a positive correlation between HIF-1α and SHH expression in human pancreatic cancer and in a retrospective study that both predict for decreased patient survival. In addition, we found that the SHH secreted by pancreatic cancer cells in hypoxia act in a paracrine manner to increase GLI activation, and the formation of collagen 1 and fibronectin, markers of desmoplasia by fibroblasts. The studies suggest that increased HIF-1α could be an initiating factor in the desmoplasia of pancreatic cancer which is amplified by cycles of decreased blood flow, increased hypoxia and further desmoplasia.
Research. 
MATERIALS AND METHODS

Reagents
Anti-HIF-1α antibody was from BD Biosciences (Sparks, MD). Anti-SHH antibody used for western blotting was from Santa Cruz Biotechnology, Inc., (Santa Cruz, California). Anti-SHH antibody used for IHC and IF staining was from Abcam Inc., (Cambridge, MA), and was specific for SHH and did not react with IHH or DHH ( Figure S1,A and B 
Human Pancreatic Cancer Immunohistochemistry
A tissue microarray (TMA) was constructed from paraffin-embedded tumor blocks using an indexed manual tissue arrayer (Advanced EDM Automation, Poway, CA). When tissue was available, cases were triple punched with 1.0 mm core needles to include 2 tumor cores and 1 adjacent normal core. Only resected pancreatic adenocarcinoma, adenosquamous and carcinoma were used in this analysis (n= 129) though not all samples were evaluated for all markers. Hematoxylin and eosin stained slides were reviewed by a pathologist (GH) and desired regions marked and transferred to the donor paraffin blocks. The master TMA blocks were sectioned at 5μm thickness and water flotation used for tissue section transfer. TMA slides were dewaxed, rehydrated and subjected to heat induced epitope retrieval with EDTA solution for 30 minutes using a BondMax™ autostainer (Leica Microsystems, Inc, Bannockburn, IL). Endogenous peroxidase was blocked and the slide was incubated for 30 minutes with HIF-1α or SHH antibody (25ug/ml) and visualized by the Bond™ Polymer Refine Detection kit (Leica Microsystems) using diaminobenzidine chromogen as substrate. Immunohistochemical staining localization was evaluated in adenocarcinoma and in peritumoral stroma separately. The vasculature was not included in the stromal component. Staining intensity was scored blinded on a scale of 0 to 3 with a score of 3 indicating strong staining. In cases where staining was heterogeneous for either compartment, the higher intensity staining was scored. Survival information was missing for 4 of the 129 patient samples in the dataset, and 11 were still alive.
Microarray
Gene expression microarray analyses were performed on RNA from MiaPaca2 wild type cells transfected with Dharmacon SMARTpool siRNA against HIF-1α (M-004018-05) or control siRNA (D-001210-05) using DharmaFECT 2 (Dharmacon, Lafayette, CO). HIF-1α knockdown efficacy was determined by Western blotting (data not shown). RNA was isolated using the 
Pentachrome staining
Pentachrome staining was carried out using the Russell-Movat Pentachrome Stain Kit (American MasterTech, catalog #KTRMP, Lodi, CA). Slides were deparaffinized with three 30min immersion in xylene, followed by two 2 minutes rehydration rinses through an alcohol series (100%, 95%, 70%), and rinsed in distilled water. Slides were placed in Verhoeff's Elastic Stain for 15min, followed by a 5 minutes tap water rinse and distilled water rinse. Elastic fibers were differentiated in 2% ferric chloride for 2 minutes (or until elastic fibers are defined). Slides were rinsed in distilled water and placed in 5% sodium thiosulfate for 1 minute. Slides were rinsed in tap water for 5 minutes, placed in 3% glacial acetic acid for 3 minutes, and then moved to a 1% Alcian blue solution for 15 minutes. Slides were rinsed in tap water, followed by distilled water, and placed in crocein scarlet-acid fuchsin for 2 minutes. After three rinses of distilled water and five sips in 1% glacial acetic acid slides were placed in two changes of 5% phosphotungstic acid for 3 minutes each. Slides were again dipped in 1% glacial acetic acid and dehydrated in 3 changes of absolute alcohol. Slides were placed in alcoholic saffron for 15 minutes, dehydrated in absolute alcohol, followed by xylene, and coverslipped.
qRT-PCR
Total RNA was isolated using the RNeasy RNA isolation kit and RNase-Free DNase set (Qiagen, Valencia, CA). qRT-PCR was performed using either a human hedgehog pathway array or specific human/mouse SYBR® Green primers for selected genes (SABioscience, Frederick, MD). The experiments were performed using the RT 2 first strand kit and RT 2 qPCR master mix Reagents (SABioscience) and analyzed in triplicates on a 7300 real time PCR 
Transfections and stable cell lines
MiaPaca2 and Panc-2 were stably transfected with shHIF-1α using the siPORTamine and lipofectamine transfection reagents respectively. Clones were selected by growing the cells 
In vitro translation assay
Expression of SHH, IHH and DHH from Myc-DDK-tagged ORF cDNA clones (catalog numbers RC222175, RC213565 and RC206715 respectively; Origene Technologies, Rockville, MD) was done using the TNT Quick coupled transcription/translation system (Promega, Madison WI). Western blotting showed reaction of the SHH antibody with SHH and not IHH or DHH (Fig S7) .
RESULTS
Tumor HIF-1α correlates with stromal SHH in human pancreatic cancer
A representative immunohistochemical staining of desmoplasia in resected pancreatic ductal carcinoma is shown in Figure 1A illustrating the infiltrative tumor associated with large amounts of stroma (i) as compared to patient matched adjacent stroma with normal architecture and focal collagen bands (ii). Figure 1A iii shows metastatic pancreatic cancer with staining for elastin, collagen, mucin and infiltrative tumor. We tested the correlation between the expression of tumor nuclear HIF-1α as a marker of hypoxia, and stromal SHH as a marker for HH signaling, in pancreatic adenocarcinoma, ductal adenocarcinoma, and adenosquamous carcinoma biopsy cores scored on a tissue microarray using immunohistochemical analysis. High expression levels of SHH were detected in 63 of 98 (64%) evaluable samples, and high expression levels of Table 1 ).
High levels of tumor HIF-1α and stromal SHH are associated with decreased patient survival
To examine the effect of HIF-1α and SHH expression on survival, tumor nuclear HIF-1α and cytoplasmic SHH immunohistochemistry (IHC) scores were divided into high (≥2.0) and low (< 2.0). We found that a high HIF-1α nuclear score was associated with significantly shorter survival (median 253 compared to 405 days, P=0.03 (log rank), n=93) ( Figure 1C) . Similarly, a high SHH score was also associated with significantly shorter survival (median 285 compared to 445 days, P = 0.0087 (log rank), n=91) ( Figure 1D ). When patients with both high tumor nuclear HIF-1α and stromal SHH scores were compared with patients with both low tumor nuclear HIF-1α and stromal SHH scores, significantly shorter survival was observed (median 248 days compared to 587 days, P = 0.0032) ( Figure 1E) . No significant association was found between PTCH expression in either tumor or stroma, and survival ( Figure S3) . A Cox proportional hazards model was used to study the effect of multiple covariates simultaneously.
When cytoplasmic SHH and nuclear HIF-1α expression levels are both in the model, a significant effect of cytoplasmic SHH expression on survival was found, with hazard ratio (HR) = 1.78 (p = 0.0016), whereas the dichotomized nuclear HIF-1α had no significant effect on survival (p=0.12). Because the Cox proportional hazards model effectively measures the effect of one variable at fixed levels of the other variables in the model, this might suggest that the apparent effect of HIF-1α expression alone on patient survival can be attributed to elevated SHH expression due to a positive correlation between the two factors. In univariate analysis, the conventional prognostic markers, pT Category, T Staging and the histologic grade are significant (P<0.05) while pN category and M Staging are marginally significant for overall survival (Table S1 and Figure S4 ).
Hypoxia induces SHH expression in pancreatic cancer cells
To test the hypothesis that HIF-1α/hypoxia may be responsible for mediating the increase in SHH we conducted a transcriptome microarray study using MiaPaCa-2 pancreatic cancer cells comparing genes transcribed in normoxia and 24 hours hypoxia (1% O 2 ), and using siRNA to HIF-1α to determine which genes were HIF-1α-dependent. We found three HH pathway genes that showed significant hypoxia/HIF-1α dependent induction; SHH ligand, and two suppressors of the pathway; PTCH1 and REN KCTD11 (Figure 2A) . qRT-PCR using a pathway array profiling the expression of 84 genes involved in hedgehog signaling confirmed the increased expression of SHH and REN KCTD11 in hypoxia in MiaPaCa-2 cells, while PTCH1
showed only a small although consistent increase in hypoxia (Table S2) 
showed accumulation of SHH in hypoxia over a period of 3 days in both MiaPaCa-2 and Panc-1 cells ( Figure S4, C and D) . Even though we observed consistent increase in REN KCTD11 RNA transcript levels in hypoxia we were not able to detect increased REN KCTD11 protein expression using Western blot or IHC analysis.
Hypoxia-induced SHH secretion by tumor cells results in paracrine SHH/GLI-1 activation in fibroblasts
Despite the hypoxic induction of SHH, MiaPaca-2 and Panc-1 cells transfected with a GLI-luciferase reporter of HH activation showed no increase in GLI activity in either normoxia or hypoxia suggesting the absence of autocrine stimulation of the cancer cells by SHH ( Figure 3A and B).
Typically, the role of HH signaling in development is mediated by paracrine effects on mesenchymal cells. In addition, it has been shown that tumors overexpressing HH ligands activate the signaling pathway in neighboring stroma cells (10-13, 19) . Hence, we next tested whether SHH secreted by pancreatic cancer cells could activate the HH pathway in fibroblasts.
A 2D co-culture of MiaPaCa-2 and NIH-3T3/GLI-luc cells showed a HIF-1α dependent increase in GLI1 reporter activity in hypoxia but not normoxia (Figure 3C ), while addition of SAG, a benzothiophene compound known to activate the HH pathway, stimulated the GLI reporter in NIH-3T3 under normoxic conditions ( Figure 3D) . RT-PCR analysis to test whether NIH-3T3
fibroblasts themselves upregulate the expression of HH pathway components in hypoxia showed no increase in SHH, PTCH, SMO, HHIP and GLI transcripts levels, (Figure 3E ) despite the increase in HIF activity during hypoxia (Figure 3E inset) .
HIF-1α-and SHH-dependent paracrine activation of HH pathway in a 3D co-culture system
To further elucidate the mechanism of HH signaling in pancreatic cancer we used a 3D culture system which more closely simulate conditions of in vivo tumor growth. Initial characterization of the system was done with Panc-1 cells stably expressing a luciferase reporter construct under the control of a hypoxia response element (Panc HRE-luc). Panc-1 HRE-luc cells grown for 5 days in air on a 3D nano-matrix form spheres ( Figure 4A ) with a hypoxic core and upregulate HIF-1α activity as demonstrated by activation of the HRE-luc reporter (Figure 4B and C) . Transfection of siHIF-1α inhibited the luciferase activity in the spheres (Figure 4B and C) . To study HH activation in 3D co-cultures of tumor cells and fibroblasts we plated NIH-3T3/GLI-luc cells together with either Panc-1, MiaPaca-2, Capan-2 or Su.86.86 for 5 days during which they continued to proliferate and assembled into 3D structures consisting of both pancreatic cancer cells and fibroblasts ( Figure 4D ). GLI transactivation measured by luciferase expression was only found when the NIH-3T3/GLI-luc cells were cocultured with Panc-1, MiaPaca-2, Capan-2 or Su.86.86 pancreatic cancer cells, but not when the NIH-3T3/GLI-luc cells were cultured alone ( Figure 4E) .
Next, we confirmed that activation of GLI in NIH-3T3 fibroblasts co-cultured with pancreatic tumor cells is mediated by HIF-1α. We used Panc-1 cells that stably express shHIF-1α and that have undetectable levels of HIF-1α as compared to shVector cells ( Figure 2D) . GLIluc expression in the NIH-3T3 fibroblasts was decreased when they were co-cultured with Panc- 
HIF-1α-dependent expression of SHH by pancreatic cancer cells induces a desmoplastic reaction in fibroblasts.
Expression of SHH has been reported to contribute to the formation of desmoplasia in pancreatic cancer (11). We therefore tested whether hypoxia and HIF-1α-induced formation of SHH by pancreatic cancer cells can induce a desmoplastic reaction in cultured fibroblasts. We Inhibiting HH signaling is an attractive approach for therapy of cancers where HH is aberrantly regulated. Therefore, we investigated whether it is possible to block the formation of HH pathway components in the tumor cells using the HIF inhibitor PX-478 ( Figure 6A ) (34) (35) .
Treatment with PX-478 of Panc-1 and MiaPaca-2 cells decreased the transcript levels of SHH and PTCH in both normoxia and hypoxia ( Figure 6B) . In addition, PX-478 treatment of 3D cocultures of NIH-3T3/GLI-luc cells with either Panc-1, Su.86.86, Capan-2 or MiaPaca2, resulted in complete inhibition of GLI activation ( Figure 6C) . Furthermore, comparing the effects of PX-478 and the SMO selective antagonist GDC-0449, in the 3D system revealed that both HIF-1α
and SHH drive HH signaling in the stroma ( Figure 6D ). This provides a proof of concept that HIF inhibitors can be used to inhibit pancreatic cancer growth by inhibiting SHH production by hypoxic cancer cells.
DISCUSSION
Pancreatic cancer is one of the most hypoxic solid tumors and HIF-1α levels are elevated in human primary pancreatic cancer as compared to normal pancreas (8, (35) (36) (37) . Our study describes a new mechanism that ties hypoxia with the elevated expression of SHH and the desmoplasia commonly seen in pancreatic cancer. We show that hypoxia, acting through elevated HIF-1α, increases the expression of SHH in pancreatic cancer cells and that patients with high expression of HIF-1α and SHH show decreased survival. We also found that in hypoxia the SHH produced by the tumor cells, acts in a paracrine manner on fibroblasts to increase desmoplasia. We propose a new model of tumor-stroma interaction whereby multiple PTCH in pancreatic cells but not in fibroblasts is not fully elucidated. However, we believe that the differential activation of the Hh pathway observed is partly attributable to the experimental settings, eg 2D versus 3D. In 2D monolayer cultures cells are homogenously exposed to hypoxia, thus likely exhibit a homogenous response and a substantial transcriptional increase of Hh target genes that can be easily detected in bulk experiments. In 3D co-culture conditions, tumor cells and fibroblasts form spheroids in which cell are exposed to a gradient of hypoxia, thus Hh activation might be patchy and exhibited only by the hypoxic fraction of cells in the spheroid, therefore accounting for the modest increase of the luciferase activity and for the lack of detectable transcriptional changes assessed by the bulk RT PCR experiments.
Our finding that SHH acts in a paracrine fashion is in accord with recent evidence showing that in various cancers, including pancreatic ductal adenocarcinoma, HH ligands fail to activate signaling in tumor epithelial cells but do activate fibroblasts in the stromal microenvironment (10-13, 19). Paracrine HH signaling has been shown to support protumorigenic communication between tumor cells and fibroblasts in the stroma and to promote tumor growth (16, 27) . Recent work suggests that pancreatic tumor cells are not competent to transduce HH signaling because they express oncogenic KRAS. Based on these studies KRAS suppresses ciliogenesis and therefore pancreatic tumor cells are devoid of primary cilia which are required for HH signaling (10, 45, 46) . In another study it was suggested that KRAS acts through dual-specificity tyrosine phosphorylation regulated kinase 1A (DYRK1B) and potentially other factors to block HH activation (46) . HH signaling is known to induce fibroblasts to produce extracellular proteins such as fibronectin and collagen I involved in desmoplasia (11). We showed that hypoxia via HIF-1α increases the expression of SHH in the pancreatic cell lines thus activating the HH pathway and desmoplasia in fibroblasts ( Figure 5 ). These results suggested that in pancreatic cancer, 
hypoxia and HIF-1α increase desmoplasia by upregulating the formation of SHH by pancreatic cancer cells, which then stimulates HH signaling and collagen I and fibronectin formation by stroma fibroblast cells.
Inhibiting HH signaling is an attractive approach for therapy of cancers where HH is aberrantly regulated and was shown to enhance delivery of chemotherapy in a mouse model of pancreatic cancer (24) . So far only SMO inhibitors have been tested in humans and have produced promising anti-tumor responses in early clinical studies (47-49). However, resistance to SMO inhibition has been shown to rapidly occur in medulloblastma patients due to mutations of SMO that do not affect HH signaling but disrupt the ability of the GDC-0449 inhibitor to bind SMO (50). An alternative approach, and one that would not be susceptible to this kind of resistance, is to inhibit the production of HH ligand by the tumor cell, for example by using a HIF-1α inhibitor that will prevent the hypoxia induced fibrosis caused by the response of fibroblasts to sHH. Moreover, since induction of SHH is only one of HIF's pleiotropic effects, this further validates HIF as a promising target for cancer therapy. We have shown that the HIF-1α inhibitor PX-478, can inhibit GLI activation in fibroblasts co-cultured with pancreatic cancer cells (Figure 6 ), strengthening the notion that HIF-1α inhibitors may be beneficial for hypoxic and HH ligand-dependent tumors such as pancreatic and prostate cancers (32) .
Based on our results, we propose the vicious cycle model of pancreatic cancer ( Figure   6E ) in which tumor hypoxia leads to increased SHH and desmoplasia which in turn further reduces blood supply to the tumor thus further augmenting tumor hypoxia. Repeating cycles of hypoxia and desmoplasia may be responsible for the highly hypoxic and fibrotic characteristics of pancreatic cancer. Breaking the cycle, for example with a HIF-1α inhibitor, provides an alternative approach for treatment of HH ligand-dependent cancers and may also help to enhance delivery of chemotherapy. 
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